deuterated oxytocin (d5OT)
Phase 2Small molecule
deuterated oxytocin (d5OT) is one of 13 small molecule programs targeting Postpartum Hemorrhage. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Postpartum Hemorrhage
#DrugCompanyPhaseTrials
1Cytotec
PfizerApproved
Pitocin
RRetrophin
Approved
Cyklokapron
JJ Molner
Approved
Pabal
AACADIA Pharmaceuticals Inc.
Phase 3
IV Oxytocin
GSKPhase 3
deuterated oxytocin (d5OT)
UUniversity of Chicago
Phase 2
Blood
UUniversity Hospital, Lille
Preclinical
Calcium Gluconate
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Misopristol
SSohag University
Preclinical
I.V Oxytocin Administration
BBezmialem Vakif University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for deuterated oxytocin (d5OT). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Chicago